## Supplementary Appendix

# Prediction of Venous Thromboembolism Based on Clinical and Genetic Factors 

David A. Kolin, M.Sc.*; Scott Kulm, B.Eng.*; Olivier Elemento, Ph.D.

*Mr. Kolin and Kulm contributed equally to this article.
Address for Correspondence:
Olivier Elemento, Ph.D.
Caryl and Israel Englander Institute for Precision Medicine
The Meyer Cancer Center
Weill Cornell Medicine
1300 York Avenue
New York, NY 10065
ole2001@med.cornell.edu

## Table of Contents:

Page 3 Table S1. Definition of Venous Thromboembolism
Page 4 Table S2. Single Nucleotide Polymorphisms Used to Calculate the Polygenic Risk Score
Page 5 Table S3. Clinical Risk Score for Venous Thromboembolism Based on Established Risk
Factors
Page 6 Table S4. Risk Group Definitions
Page 7 Table S5. Characteristics of the Participants at Baseline
Page 8 Table S6. Risk of Venous Thromboembolism with Duration of Contraception Use
Page 9 Table S7. The Five Most Common Oral Contraceptive Pills Amongst Current Users
Page 10 Table S8. Univariate Risk Ratios for Death from Venous Thromboembolism
Page 11 Table S9. Risk of Venous Thromboembolism with Common Non-Cancer Illnesses, Adjusted for Common Medications
Page 12 Figure S1. Kaplan-Meier Curves for Four Individual Clinical Factors
Page 13 Figure S2. Minimally Adjusted Risk of Venous Thromboembolism with Established Clinical Risk Factors
Page 14 Figure S3. Minimally Adjusted Risk of Venous Thromboembolism with Common Cancer Subtypes
Page 15 Figure S4. Minimally Adjusted Risk of Venous Thromboembolism with Common Medications
Page 16 Figure S5. Minimally Adjusted Risk of Venous Thromboembolism with Common NonCancer Illnesses
Page 17 Figure S6. Minimally Adjusted Risk of Venous Thromboembolism with Common Fracture Sites
Page 18 Figure S7. Number of Incident Venous Thromboembolic Events Amongst Participants Page 19 Figure S8. Polygenic Risk Score Stratified by the Number of Venous Thromboembolic Events
Page 20 Figure S9. Hazard Ratios for Sub-Classified Venous Thromboembolic Events with the Clinical and Genetic Scores
Page 21 Figure S10. Interactions Between Individual Covariates and the Genetic Score Page 22 Figure S11. Associations Between Traits Relevant to Venous Thromboembolism, Polygenic Risk Scores of These Traits, or Interactions Between the Two
Page 23 Figure S12. Associations Derived from a Cox-proportional Hazard Model for Possible Frailty within the Population
Page 24 Figure S13. Hazard Ratios for Venous Thromboembolism at Various Time Points Page 25 Figure S14. Kaplan-Meier Curve of the Combined Score

Table S1. Definition of Venous Thromboembolism

| Outcome | ICD-10 | ICD-9 |
| :--- | :--- | :--- |
| Venous thromboembolism |  |  |
| Pulmonary embolism (PE) | I26 | 415 |
| Deep vein thrombosis (DVT) | I80-I82 | $451-453$ |

Table S2. Single Nucleotide Polymorphisms Used to Calculate the Polygenic Risk Score

| Chromosome | Position | P-value | Risk <br> Estimate | Risk Allele | Lead SNP | Study | Study Coefficient |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 169165889 | 2e-12 | 2.02 | C | rs16861990 | $\begin{array}{\|l} \hline \text { Heit et al., } \\ 2012 \\ \hline \end{array}$ | 0.68 |
| 1 | 169467654 | 1.2e-08 | 2.38 | A | rs1894692 | de Haan et al., 2018 | -0.13 |
| 1 | 169481223 | 7.9e-09 | 2.06 | G | rs6427196 | de Haan et al., 2018 | -0.13 |
| 1 | 169490392 | 9.1e-09 | 2.05 | C | rs2420370 | de Haan et al., 2018 | -0.13 |
| 1 | 169491555 | 1.2e-08 | 2.03 | A | rs2420371 | de Haan et al., 2018 | -0.13 |
| 1 | 169542517 | $3 \mathrm{e}-11$ | 1.2 | T | rs4524 | Germain et al., 2015 | -0.85 |
| 1 | 169544768 | 2e-26 | 2.52 | A | rs1018827 | Germain et al., 2011 | 0.05 |
| 1 | 169549811 | $4 \mathrm{e}-137$ | 2.93 | T | rs6025 | $\begin{array}{\|l} \hline \text { Hinds et al., } \\ 2016 \\ \hline \end{array}$ | 0.17 |
| 2 | 42372465 | 2e-07 | 1.36 | G | rs72798544 | $\begin{array}{\|l} \hline \text { Hinds et al., } \\ 2016 \\ \hline \end{array}$ | 0.17 |
| 3 | 1004354 | 2e-06 | 1.18 | C | rs6764623 | $\begin{array}{\|l} \hline \text { Tang et al., } \\ 2013 \\ \hline \end{array}$ | 0.07 |
| 4 | 154599778 | $2 \mathrm{e}-13$ | 1.53 | A | rs7659024 | Germain et al., 2011 | 0.05 |
| 4 | 154623920 | 2e-19 | 1.22 | T | rs7654093 | $\begin{array}{\|l} \hline \text { Hinds et al., } \\ 2016 \\ \hline \end{array}$ | 0.17 |
| 4 | 186266940 | $3 \mathrm{e}-14$ | 1.24 | G | rs4253399 | $\begin{array}{\|l} \text { Tang et al., } \\ 2013 \\ \hline \end{array}$ | 0.07 |
| 4 | 186277851 | 1e-23 | 1.27 | C | rs4253417 | Germain et al., 2015 | -0.85 |
| 9 | 133257522 | $6 \mathrm{e}-12$ | 1.47 | G | rs8176719 | $\begin{array}{\|l} \hline \text { Heit et al., } \\ 2012 \\ \hline \end{array}$ | 0.68 |
| 9 | 133279294 | 3e-16 | 1.65 | T | rs495828 | $\begin{aligned} & \text { Heit et al., } \\ & 2012 \end{aligned}$ | 0.68 |
| 10 | 69458890 | $3 \mathrm{e}-07$ | 1.165 | G | rs17490626 | $\begin{array}{\|l} \hline \text { Hinds et al., } \\ 2016 \\ \hline \end{array}$ | 0.17 |
| 10 | 69485520 | 2e-16 | 1.31 | T | rs78707713 | Germain et al., 2015 | -0.85 |
| 15 | 31501727 | $3 \mathrm{e}-06$ | 1.15 | A | rs7164569 | $\begin{array}{\|l\|} \hline \text { Tang et al., } \\ 2013 \\ \hline \end{array}$ | 0.07 |
| 19 | 10631494 | $3 \mathrm{e}-15$ | 1.21 | G | rs2288904 | Germain et al., 2015 | -0.85 |
| 19 | 10632450 | 6e-09 | 1.145 | T | rs9797861 | $\begin{array}{\|l} \hline \text { Hinds et al., } \\ 2016 \\ \hline \end{array}$ | 0.17 |

Table S3. Clinical Risk Score for Venous Thromboembolism Based on Established Risk Factors

| Clinical Risk Factors | Points (Total $=10$ ) |
| :--- | :--- |
| Sex | Female $-0 ;$ Male -1 |
| Age, years | $<50-0 ; \geq 50$ to $<60-1 ; \geq 60-2$ |
| Body mass index, $\mathbf{k g} / \mathbf{m}^{\mathbf{2}}$ | $<25-0 ; \geq 25$ to $<30-1 ; \geq 30-2$ |
| Cancer | No $-0 ;$ Yes -1 |
| Smoking | Not current $-0 ;$ Current -1 |
| Fracture in the last five years | No $-0 ;$ Yes -1 |
| Previous venous thromboembolism | No $-0 ;$ Yes -2 |

Previous venous thromboembolism was defined as previous deep vein thrombosis or previous pulmonary embolism.

Table S4. Risk Group Definitions

| Risk Group | Genetic Score (\%) | Clinical Score (\%) |
| :---: | :---: | :---: |
| Low | -3.59 to $-0.80(19.9)$ | 0 to $2(38.1)$ |
| Medium | -0.80 to $0.74(80.0)$ | 3 to $4(49.3)$ |
| High | 0.74 to $6.19(20.1)$ | 5 to $10(12.6)$ |

Table S5. Characteristics of the Participants at Baseline

| Variable | Total (N = 502,536) |
| :--- | :--- |
| Sex - no. (\%) |  |
| Female | $273,402(54.4)$ |
| Male | $229,134(45.6)$ |
| Age, years - mean (95\% CI) | $56.53(56.51-56.55)$ |
| Body mass index, kg/m $\mathbf{~}$ - mean (95\% CI) | $27.43(27.42-27.45)$ |
| Previous cancer diagnosis - no. (\%) |  |
| No | $459,974(91.5)$ |
| Yes | $41,700(8.3)$ |
| Unknown | $862(0.2)$ |
| Smoking status - no. (\%) |  |
| Never | $273,537(54.4)$ |
| Previous | $173,030(34.4)$ |
| Current | $52,979(10.5)$ |
| Declined to answer | $2059(0.4)$ |
| Unknown | $891(0.2)$ |
| Alcohol intake frequency - no. (\%) |  |
| Never | $40,648(8.1)$ |
| Special occasions only | $58,012(11.5)$ |
| One to three times a month | $55,858(11.1)$ |
| Once or twice a week | $129,297(25.7)$ |
| Three or four times a week | $115,445(23.0)$ |
| Daily or almost daily | $101,774(20.3)$ |
| Prefer not to answer | $605(0.1)$ |
| Unknown | $897(0.2)$ |
| Ever use oral contraceptive pill - no. (\%) |  |
| No | $51,532(18.8)$ |
| Yes | $220,446(80.6)$ |
| Do not know | $444(0.2)$ |
| Prefer not to answer | $497(0.2)$ |
| Unknown | $483(0.2)$ |
| Ever use hormone replacement therapy - no. (\%) |  |
| No | $167,903(61.4)$ |
| Yes | $103,919(38.0)$ |
| Do not know | $800(0.3)$ |
| Prefer not to answer | $297(0.1)$ |
| Unknown | $483(0.2)$ |
| Fracture in the last 5 years - no. (\%) | $451,266(90.0)$ |
| No | $47,466(9.4)$ |
| Yes | $2,533(0.5)$ |
| Do not know | $340(<0.1)$ |
| Declined to answer | $931(0.2)$ |
| Unknown |  |
|  |  |

Table S6. Risk of Venous Thromboembolism with Duration of Contraception Use

| Duration of <br> Contraception Use <br> (Years) | No. of <br> Patients | No. of <br> Events | Hazard Ratio <br> (95\% CI) | P-value |
| :--- | :--- | :--- | :--- | :--- |
| Other | 77,900 | 820 | 1 |  |
| $>\mathbf{0}$ to $<\mathbf{1 0}$ | 99,601 | 779 | $0.93(0.83-1.04)$ | 0.29 |
| $\geq \mathbf{1 0}$ to $<\mathbf{2 0}$ | 66,377 | 408 | $0.87(0.76-1.00)$ |  |
| $\geq \mathbf{2 0}$ | 29,524 | 151 | $0.81(0.67-0.98)$ |  |

Cox regression models were adjusted for sex, age, body mass index, previous cancer diagnosis, smoking status, alcohol intake frequency, use of hormone replacement therapy, fracture in the last five years, previous deep vein thrombosis, previous pulmonary embolism, and the first four principal components of ancestry. The p-value was calculated with duration of contraception use coded as a continuous variable.

Table S7. The Five Most Common Oral Contraceptive Pills Amongst Current Users

| Oral Contraceptive Pill | Total $\mathbf{( N = 2 , 5 9 8 )}$ |
| :--- | :--- |
| Cerazette $\mathbf{( 7 5} \boldsymbol{\mu}$ g tablet) | 935 |
| Micronor tablet | 558 |
| Microgynon 30 tablet | 518 |
| Femulen tablet | 305 |
| Noriday tablet | 282 |

Table S8. Univariate Risk Ratios for Death from Venous Thromboembolism

| Variable | No. of Patients | No. of Events | Risk Ratio (95\% CI) |
| :---: | :---: | :---: | :---: |
| Sex |  |  |  |
| Female | 273,402 | 102 | 1 |
| Male | 229,134 | 133 | 1.56 (1.20-2.01) |
| Age, years |  |  |  |
| $<50$ | 117,885 | 21 | 1 |
| $\geq 50$ to $<60$ | 167,158 | 60 | 2.01 (1.23-3.31) |
| $\geq 60$ | 217,493 | 154 | 3.97 (2.52-6.27) |
| Body-mass index, kg/m ${ }^{2}$ |  |  |  |
| <18.5 | 2,626 | 3 | 5.46 (1.68-17.76) |
| $\geq 18.5$ to $<25$ | 162,423 | 34 | 1 |
| $\geq 25$ to $<30$ | 212,127 | 79 | 1.78 (1.19-2.66) |
| $\geq 30$ to $<35$ | 87,557 | 60 | 3.27 (2.15-4.99) |
| $\geq 35$ to $<40$ | 24,994 | 26 | 4.97 (2.98-8.28) |
| $\geq 40$ | 9,704 | 28 | 13.78 (8.36-22.72) |
| Previous cancer diagnosis |  |  |  |
| No | 459,974 | 211 | 1 |
| Yes | 41,700 | 23 | 1.20 (0.78-1.85) |
| Ever smoked |  |  |  |
| Never | 273,537 | 113 | 1 |
| Previous | 173,070 | 80 | 1.12 (0.84-1.49) |
| Current | 52,979 | 38 | 1.74 (1.20-2.51) |
| Alcohol intake frequency |  |  |  |
| Never | 40,648 | 26 | 1 |
| Special occasions only | 58,012 | 47 | 1.27 (0.78-2.04) |
| One to three times a month | 55,858 | 28 | 0.78 (0.46-1.34) |
| Once or twice a week | 129,297 | 53 | 0.64 (0.40-1.02) |
| Three or four times a week | 115,445 | 43 | 0.58 (0.36-0.95) |
| Daily or almost daily | 101,774 | 37 | 0.57 (0.34-0.94) |
| Ever use oral contraceptive pill |  |  |  |
| No | 51,532 | 31 | 1 |
| Yes | 220,446 | 69 | 0.52 (0.34-0.79) |
| Ever use hormone-replacement therapy |  |  |  |
| No | 167,903 | 52 | 1 |
| Yes | 103,919 | 49 | 1.52 (1.03-2.25) |
| Fracture in the last 5 years |  |  |  |
| No | 451,266 | 214 | 1 |
| Yes | 47,466 | 20 | 0.89 (0.56-1.40) |
| Previous deep veins thrombosis |  |  |  |
| No | 492,582 | 219 | 1 |
| Yes | 9,323 | 16 | 3.86 (2.32-6.41) |
| Previous pulmonary embolism |  |  |  |
| No | 498,417 | 221 | 1 |
| Yes | 3,955 | 14 | 7.98 (4.66-13.69) |

Table S9. Risk of Venous Thromboembolism with Common Non-Cancer Illnesses, Adjusted for Common Medications

| Common Non-Cancer <br> Illness | Additional Covariates | Hazard Ratio <br> $\mathbf{( 9 5 \%}$ CI) |
| :--- | :--- | :--- |
| Hypercholesterolemia | Atorvastatin, simvastatin, and pravastatin | $1.00(0.90-1.11)$ |
| Asthma | Beclomethasone, beconase, and becotide | $1.14(1.04-1.25)$ |
| Osteoarthritis | Aspirin, ibuprofen, and diclofenac | $1.17(1.06-1.29)$ |
| Depression | Amitriptyline, citalopram, and fluoxetine | $1.19(1.03-1.37)$ |
| Diabetes | Metformin, insulin products, and glibenclamide | $0.86(0.71-1.04)$ |

Cox regression models were adjusted for sex, age, body mass index, previous cancer diagnosis, smoking status, alcohol intake frequency, use of oral contraceptive pills, use of hormone replacement therapy, fracture in the last five years, previous deep vein thrombosis, previous pulmonary embolism, and the first four principal components of ancestry. Common illness-specific medications were added to each model to test mediation by medication use.

Figure S1. Kaplan-Meier Curves for Four Individual Clinical Factors


The Kaplan-Meier curves were adjusted for the first four principal components of ancestry, age, sex, body mass index, previous venous thromboembolism, smoking status, previous cancer diagnosis, alcohol intake frequency, and fracture in the last five years.

Figure S2. Minimally Adjusted Risk of Venous Thromboembolism with Established Clinical Risk Factors


Minimally adjusted Cox regression models were adjusted for sex, age, body mass index, and smoking status.

Figure S3. Minimally Adjusted Risk of Venous Thromboembolism with Common Cancer Subtypes

|  | No. of <br> Patients | No. of <br> Events |
| :--- | :--- | :--- | :--- |
| Cancer Subtype (vs. no cancer) |  |  |

Minimally adjusted Cox regression models were adjusted for sex, age, body mass index, and smoking status.

Figure S4. Minimally Adjusted Risk of Venous Thromboembolism with Common Medications


Minimally adjusted Cox regression models were adjusted for sex, age, body mass index, and smoking status.

Figure S5. Minimally Adjusted Risk of Venous Thromboembolism with Common Non-Cancer Illnesses


Minimally adjusted Cox regression models were adjusted for sex, age, body mass index, and smoking status.

Figure S6. Minimally Adjusted Risk of Venous Thromboembolism with Common Fracture Sites


Minimally adjusted Cox regression models were adjusted for sex, age, body mass index, and smoking status.

Figure S7. Number of Incident Venous Thromboembolic Events Amongst Participants


Figure S8. Polygenic Risk Score Stratified by the Number of Venous Thromboembolic Events


Figure S9. Hazard Ratios for Sub-Classified Venous Thromboembolic Events with the Clinical and Genetic Scores


Event sub-classifications were coded as follows: pulmonary embolism (I26), phlebitis (I80), and embolism and thrombosis (I82). Hazard ratios were calculated using Cox-proportional hazard models including the factor indicated and adjusted for the first four principal components of ancestry. Hazard ratios were calculated with the clinical and genetic scores coded on a continuous scale, with a range from 0 to 9 for the clinical score and -3.59 to 6.19 for the genetic score.

Figure S10. Interactions Between Individual Covariates and the Genetic Score


Interactions were tested between the individual covariates indicated and the genetic score. The p-values for interactions were computed using a Cox-proportional hazard model adjusted for the first four principal components of ancestry (PC1 to PC4), age, sex, previous venous thromboembolism, body mass index (BMI), previous cancer diagnosis, smoking status, alcohol intake frequency, and fracture in the last five years.

Figure S11. Associations Between Traits Relevant to Venous Thromboembolism, Polygenic Risk Scores of These Traits, or Interactions Between the Two


The relevance of traits associated with venous thromboembolism was analyzed through both genetics, via a polygenic risk score calculated to best predict the relevant trait, and outcomes of the relevant trait determined through related ICD codes. Specifically, the associated traits included venous thromboembolism (VT), pulmonary embolism (PE), body mass index (BMI), diabetes, myocardial Infarction (MI), pulmonary artery disease (PAD), stroke, and varicose veins (VV). Five Cox-proportional hazard models were constructed for this analysis: basic, which included principal components, age, sex, and previous venous thromboembolism; scores, which included the basic model with the polygenic risk scores for all traits; diagnosis, which is the basic model with the binary outcome for each trait; interaction, which is the basic model with the interaction terms between each trait's outcome and score; and multiplicative, which is the basic model, trait scores, trait outcomes, and the interaction terms between the trait outcomes and scores. The negative $\log _{10} \mathrm{p}$-value for each covariate in these models is reported, with values above 10 rounded to 10 .

Figure S12. Associations Derived from a Cox-proportional Hazard Model for Possible Frailty within the Population


A frailty analysis was conducted to check for additional clustering among the participants. Four Cox-proportional hazard models were computed. The genetic model included the first four principal components of ancestry, age, sex, previous venous thromboembolism and the genetic score. The combined model included the first four principal components of ancestry and the combined score. The clinical model included the first four principal components of ancestry and the clinical score. The basic model included the first four principal components of ancestry, age, sex, and previous venous thromboembolism.

Figure S13. Hazard Ratios for Venous Thromboembolism at Various Time Points


A time dependent analysis was conducted to check for any strong temporal relationships between three covariates and venous thromboembolic events. Three of the covariates (genetic score, age, and body mass index [BMI]) were chosen due to their strong association with venous thromboembolism. The maximum study length data frame of events was truncated at each year. The Cox-proportional hazard model was adjusted for the first four principal components of ancestry, age, sex, BMI, previous venous thromboembolism, previous cancer diagnosis, alcohol intake frequency, smoking status, the genetic score, and fracture in the last five years. Hazard ratios were calculated with each covariate of interest coded on a continuous scale.

Figure S14. Kaplan-Meier Curve of the Combined Score


The Kaplan-Meier curve for the combined score was adjusted for the first four principal components of ancestry.

